Thromb Haemost 2000; 83(01): 173-174
DOI: 10.1055/s-0037-1613776
Letters to the Editor
Schattauer GmbH

Is there a Role for Anti-phospholipid-binding Protein Antibodies in the Pathogenesis of Thrombosis in Behcet’s Disease?

R. Priori
1   From the Cattedra di Allergologia e Immunologia Clinica III, Clinica Medica I
,
F. Conti
1   From the Cattedra di Allergologia e Immunologia Clinica III, Clinica Medica I
,
V. Pittoni
1   From the Cattedra di Allergologia e Immunologia Clinica III, Clinica Medica I
,
T. Garofalo
2   Dipartimento di Medicina Sperimentale e Patologia, Università “La Sapienza” Roma, Italy
,
M. Sorice
2   Dipartimento di Medicina Sperimentale e Patologia, Università “La Sapienza” Roma, Italy
,
G. Valesini
1   From the Cattedra di Allergologia e Immunologia Clinica III, Clinica Medica I
› Author Affiliations
Further Information

Publication History

Received 03 May 1999

Accepted 21 June 1999

Publication Date:
06 December 2017 (online)

 

 
  • References

  • 1 Kaklamani VG, Vaiopoulos G, Kaklamanis GPhaedon. Behcet’s disease. Semin Arthr Rheum 1998; 27: 197-217.
  • 2 Shimizu T, Ehrlich GE, Inaba G, Hayashi K. Behcet’s disease (Behcet’s syndrome). Semin Arthr Rheum 1979; 08: 223-60.
  • 3 Dilsen N, Konice K, Aral O, Ocal L, Inanc M, Gul A. Risk factor for vital organ involvement in Behcet’s disease. In Godeau P, Wechsler B. eds. Behcet’s disease. New York: Elsevier Science; 1993: 165-9.
  • 4 Hatzinicolaou P, Vayolopous G, Mavropoulos S. et al. Vascular manifestations in Behcet’s disease. Br J Rheumatol 1992; 31: 284-5.
  • 5 Kuzu MA, Ozaslan C, Koksoy C, Gurler A, Tuzuner A. Vascular involvement in Behcet’s disease: 8-year audit. World J Surg 1994; 18: 948-54.
  • 6 Pande I, Uppal SS, Kailash S, Kumar A, Maloviya AN. Behcet’s disease in India: a clinical, immunological, immunogenetic and outcome study. Br J Rheumatol 1995; 34: 825-30.
  • 7 Zouboulis CC, Buttner P, Tebbe B, Orfanos CE. Anticardiolipin antibodies in Adamantiades-Behcet’s disease. Br J Dermatol 1993; 128: 281-4.
  • 8 Al-Daalan AN, al-Ballaa SR, al-Janadi MA, Bohlega S, Bahabri S. Association of anti-cardiolipin antibodies with vascular thrombosis and neurological manifestation of Behcet’s disease. Clin Rheumatol 1993; 12: 28-30.
  • 9 Bergman R, Lorber M, Lerner M, Brik R, Friedman-Birnbaum R. Anticardiolipin antibodies in Behcet’s disease. J Dermatol 1990; 17: 164-7.
  • 10 Odzemir Y, Onder F, Yarangumeli A, Kucukkuyumcu C, Kural G. Anticardiolipin antibodies and retinal vascular complications in Behcet’s disease. Ophtalm Surg Lasers 1997; 28: 653-6.
  • 11 Pivetti-Pezzi P, Priori R, Catarinelli G. et al. Markers of vascular injury in behcet’s disease associated with retinal vasculitis. Ann Ophtalmol 1992; 24: 411-4.
  • 12 Hull RG, Harris EN, Gharavi E. et al. Anticardiolipin antibodies: occurrence in Behcet’s syndrome. Ann Rheum Dis 1984; 43: 746-8.
  • 13 Alarcon-Segovia D, Cabral AR. The concept and classification of antiphospholipid/cofactor syndromes. Lupus 1996; 05: 364-7.
  • 14 Sorice M, Pittoni V, Circella A, Misasi R, Conti F, Longo A, Pontieri GM, Valesini G. Anti-prothrombin but not “pure” anti-cardiolipin antibodies are associated with the clinical features of the antiphospholipid antibodies syndrome. Thromb Haemost 1998; 80: 713-5.
  • 15 Guermazi S, Hamza M, Dellagi K. Protein S deficiency and antibodies to protein S in patients with Behcet’s disease. Thromb Res 1997; 86: 197-204.
  • 16 bInternational study group for Behcet’s disease. Criteria for diagnosis of Behcet’s disease. Lancet 1990; 335: 1078-80.